Axinn Successfully Argues for Claim Construction in Mayne v. Merck
December 27, 2016
A team of Axinn attorneys successfully argued on behalf of Mayne Pharma International Pty Ltd. in a claim construction hearing in the patent infringement action, Mayne Pharma International Pty Ltd. v. Merck & Co., Inc. and Merck Sharp & Dohme Corp. On December 27, 2016, Judge Leonard P. Stark of the United States District Court for the District of Delaware issued a favorable opinion and order construing the claims to be limited to humans, as well as rejecting Merck’s contentions that the claims are invalid for indefiniteness.
The patent infringement matter alleges that Merck’s Noxafil® tablets infringe Mayne's U.S. Patent No. 6,881,745, which relates to pharmaceutical compositions for poorly soluble, antifungal drugs.
The team of Axinn attorneys consisted of Jason Murata, Thomas Hedemann, and Matt Murphy.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
The Empty Chair in Antitrust Conspiracy Cases
Webinar
Antitrust
USC Gould/Analysis Group Global Competition Law Thought Leadership Conference
Speaking Engagement
Antitrust
17th ACI Summit on Biosimilars & Innovator Biologics
Speaking Engagement
Intellectual Property
GCR Live: Europe 2026
Speaking Engagement
Antitrust
20th Annual IBA Competition Mid-Year Conference
Speaking Engagement
Antitrust
Axinn Partners Named to Lawdragon 500 Leading Global Litigators 2026
News
Litigation & Trials
Turning Up the Heat: Federal Circuit Sets the Temperature for pH Measurements in Precedential Opinion
Axinn Viewpoints
Intellectual Property
Axinn Represents Tecomet in Closing of Merger with Orchid Orthopedic
Deals & Cases
Antitrust
Recent Benchmarking Suits Highlight DOJ Enforcement Risks
Byline Articles
Antitrust
“Old Crime, New Code” – DOJ Outlines its Views on When Software and AI Can Facilitate Collusion
Axinn Viewpoints
Antitrust
